Pirfenidone

In the US, Pirfenidone (pirfenidone systemic) is a member of the drug class miscellaneous uncategorized agents and is used to treat Idiopathic Pulmonary Fibrosis.

US matches:

• Pirfenidone

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L04AX05

CAS registry number (Chemical Abstracts Service)

0053179-13-8

Chemical Formula

C12-H11-N-O

Molecular Weight

185

Therapeutic Categories

Anti-inflammatory agent

Antifibrotic agent

Treatment of idiopathic pulmonary fibrosis

Chemical Names

5-Metyl-1-phenyl-1-H-pyridin-2-one (JAN)

5-Metyl-1-phenyl-2(1H)-pyridone (WHO, USAN)

Foreign Names

• Pirfenidonum (Latin)
• Pirfenidon (German)
• Pirfénidone (French)
• Pirfenidona (Spanish)

Generic Names

• Pirfenidone (OS: USAN, JAN, BAN)
• AMR-69 (IS)
• S-7701 (IS)

Brand Names

• Esbriet
  InterMune, Austria; InterMune, Belgium; InterMune, Denmark; InterMune, Spain; InterMune, Finland; InterMune, Lithuania; InterMune, Norway; InterMune, Poland; InterMune, United States; InterMune Canada, Canada; InterMune Nordics, Sweden; Roche, Germany; Roche, France; Roche, Croatia (Hrvatska); Roche, Ireland; Roche, Iceland; Roche, Slovenia; Roche Products, United Kingdom
• Pirespa
  Shionogi Seiyaku, Japan

Glossary

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer